AI Article Synopsis
- - Respiratory Syncytial Virus (RSV) significantly impacts infants with acute lower respiratory tract infections, and while there’s currently only one monoclonal antibody available, a new one called Nirsevimab has shown promising results in trials.
- - The study used a dynamic model to evaluate various Nirsevimab administration strategies, including seasonal and catch-up approaches, to determine their cost-effectiveness against the existing treatment, Palivizumab.
- - Nirsevimab would need to be priced at £63 or less per dose to cost-effectively replace Palivizumab for seasonal administration, with an extended seasonal approach being optimal at £32/dose or less, indicating its potential value beyond just high-risk infants in
Article Abstract
Introduction: Respiratory Syncytial Virus (RSV) is a major cause of acute lower respiratory tract infections (ALRI) in infants. There are no licensed vaccines and only one monoclonal antibody available to protect infants from disease. A new and potentially longer-lasting monoclonal antibody, Nirsevimab, showed promising results in phase IIb/III trials. We evaluate the cost-effectiveness of Nirsevimab intervention programmes in England and Wales.
Methods: We used a dynamic model for RSV transmission, calibrated to data from England and Wales. We considered a suite of potential Nirsevimab programmes, including administration to all neonates (year-round); only neonates born during the RSV season (seasonal); or neonates born during the RSV season plus infants less than six months old before the start of the RSV season (seasonal + catch-up).
Results: If administered seasonally to all infants at birth, we found that Nirsevimab would have to be priced at £63 or less per dose for at least 50% certainty that it could cost-effectively replace the current Palivizumab programme, using an ICER threshold of £20,000/QALY. An extended seasonal programme which includes a pre-season catch-up becomes the optimal strategy at a purchasing price of £32/dose or less for at least 50% certainty. At a purchasing price per dose of £5-32, the annual implementation costs of a seasonal programme could be as high as £2 million before a switch to a year-round strategy would be optimal.
Discussion: Nirsevimab has the potential to be cost-effective in England and Wales not only for use in high-risk infants.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2022.10.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Impact of Childhood Dental Attendance on Perceived Adult Oral Health: The British Cohort Study.
J Public Health Dent
January 2025
Dental Public Health, Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, UK.
Objective: To evaluate the effect of childhood dental attendance pattern on self-rated oral health in middle adulthood among the British population.
Methods: Data from the 1970 British Cohort Study involving participants born in England, Scotland, and Wales were used. Self-rated oral health was assessed at age 46.
Antibiotic prophylaxis for patients undergoing dental care: a multi-centre evaluation in community and hospital dental services.
Br Dent J
January 2025
Consultant in Special Care Dentistry, Guy´s and St Thomas´ NHS Foundation Trust, London, UK.
Background Infective endocarditis (IE) is a life-threatening condition known to be associated with transient bacteraemia, the source of which can be the oral cavity. Scottish Dental Clinical Effectiveness Programme (SDCEP) 2018 implementation advice was introduced to provide practical guidance on National Institute for Health and Care Excellence Clinical Guideline 64 (2016) for management of patients at risk of IE undergoing dental treatment.Aims To assess current compliance with SDCEP's Antibiotic prophylaxis against infective endocarditis in six UK special care dentistry services.
View Article and Find Full Text PDFMethodology for the Positive Voices 2022 Survey of People With HIV Accessing Care in England, Wales, and Scotland: Cross-Sectional Questionnaire Study.
JMIR Res Protoc
January 2025
UK Health Security Agency, London, United Kingdom.
Background: Due to advances in treatment, HIV is now a chronic condition with near-normal life expectancy. However, people with HIV continue to have a higher burden of mental and physical health conditions and are impacted by wider socioeconomic issues. Positive Voices is a nationally representative series of surveys of people with HIV in the United Kingdom.
View Article and Find Full Text PDFSpontaneous Cloacal Prolapse in a Farm Ostrich (Struthio camelus): Case Management and Literature Review.
Vet Med Sci
January 2025
Department of Surgery and Obstetrics, Faculty of Veterinary Science, Bangladesh Agricultural University, Mymensingh, Bangladesh.
Captive ratites, including the ostrich (Struthio camelus), are susceptible to various gastrointestinal conditions. However, spontaneous cloacal prolapse is a relatively less frequent diagnosis. This report details the clinical management of cloacal prolapse in an ostrich, including a brief literature review.
View Article and Find Full Text PDFHealthy Lifestyle Care vs Guideline-Based Care for Low Back Pain: A Randomized Clinical Trial.
JAMA Netw Open
January 2025
University Centre for Rural Health, School of Health Sciences, University of Sydney, Lismore, New South Wales, Australia.
Importance: An unhealthy lifestyle is believed to increase the development and persistence of low back pain, but there is uncertainty about whether integrating support for lifestyle risks in low back pain management improves patients' outcomes.
Objective: To assess the effectiveness of the Healthy Lifestyle Program (HeLP) compared with guideline-based care for low back pain disability.
Design, Setting, And Participants: This superiority, assessor-blinded randomized clinical trial was conducted in Australia from September 8, 2017, to December 30, 2020, among 346 participants who had activity-limiting chronic low back pain and at least 1 lifestyle risk (overweight, poor diet, physical inactivity, and/or smoking), referred from hospital, general practice, and community settings.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!